REGN

Regeneron Pharmaceuticals
D

REGN

Arincen73/100B

Regeneron Pharmaceuticals return on equity (ROE)

Regeneron Pharmaceuticals's return on equity is 14.38%: net income of 4.82B USD over the last twelve months on shareholders' equity of 33.50B USD.

Today
14.38%
Average, 5 years
19.18%
Low, 5 years
13.65%
High, 5 years
43.03%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 4.82B ÷ 33.50B = 14.38%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

What drives Regeneron Pharmaceuticals's return on equity?

Net margin
31.4%
profit on each dollar of sales
Asset turnover
0.35×
sales on each dollar of assets
Equity multiplier
1.30×
assets on each dollar of equity
Return on equity
14.4%
FY2025
  • FY202531.4% × 0.35 × 1.30 = 14.4%
  • FY202431.1% × 0.38 × 1.29 = 15.0%
  • FY202330.1% × 0.40 × 1.27 = 15.2%
  • FY202235.6% × 0.42 × 1.29 = 19.1%
  • FY202150.2% × 0.63 × 1.36 = 43.0%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today14.38%4.82B33.50B
FY202531 Dec 202514.41%4.50B31.26B
FY202431 Dec 202415.03%4.41B29.35B
FY202331 Dec 202315.22%3.95B25.97B
FY202231 Dec 202219.14%4.34B22.66B
FY202131 Dec 202143.03%8.08B18.77B
FY202031 Dec 202031.86%3.51B11.03B
FY201931 Dec 201919.08%2.12B11.09B
FY201831 Dec 201827.91%2.44B8.76B
FY201731 Dec 201719.51%1.20B6.14B
FY201631 Dec 201620.13%895.52M4.45B
FY201531 Dec 201517.40%636.06M3.65B
FY201431 Dec 201413.69%348.07M2.54B
FY201331 Dec 201321.74%424.36M1.95B
FY201231 Dec 201260.24%750.27M1.25B
FY201131 Dec 2011-45.65%-221.76M485.73M
FY201031 Dec 2010-19.79%-104.47M527.82M
FY200931 Dec 2009-17.10%-67.83M396.76M
FY200831 Dec 2008-19.75%-82.71M418.85M
FY200731 Dec 2007-22.94%-105.60M460.27M
FY200631 Dec 2006-47.24%-102.34M216.62M
FY200531 Dec 2005-83.72%-95.45M114.00M
FY200431 Dec 200422.84%41.70M182.54M
FY200331 Dec 2003-78.07%-107.46M137.64M
FY200231 Dec 2002-85.20%-124.38M145.98M
FY200131 Dec 2001-28.60%-76.18M266.36M
FY200031 Dec 2000-12.75%-23.22M182.13M
FY199931 Dec 1999-21.10%-23.10M109.50M
FY199831 Dec 1998-6.55%-8.60M131.20M
FY199731 Dec 1997-8.35%-11.60M138.90M
FY199631 Dec 1996-30.31%-32.40M106.90M
FY199531 Dec 1995-34.61%-23.50M67.90M
FY199431 Dec 1994-45.75%-30.70M67.10M
FY199331 Dec 1993-40.55%-39.90M98.40M
FY199231 Dec 1992-21.90%-19.10M87.20M
FY199131 Dec 1991-4.24%-4.50M106.20M
FY199031 Dec 1990-27.05%-3.30M12.20M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about Regeneron Pharmaceuticals's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.